Wyeth

Pfizer Corporation

Christopher John Corcoran

Lisa Anne Collins-Racie

Bethany Annis Freeman

Carl Ralph Flannery

Edward R LaVallie

Edward Roland Lavallie

Geertruida Machteld Veldman

Lioudmila Tchistiakova

Kimberly Ann Marquette

Xiang-Yang Tan

Riyez Karim

Katy Evangelia Georgiadis

John Adam Nowak

Kathleen N Tomkinson

Stephane Olland

Thomas Saltmarsh Rush, Iii

Thomas E McDonagh

Stewart Andrews Mackie

Tara K Crawford

Ravindra Kumar

Phaik-Eng Sum

Lisa A Racie

Lidia Mosyak

Michael J Agostino

Xiaotian Zhong

Lydia Mosyak

Tracy Hebert

Weilan Zeng

Lioudmila Gennadievna Tchistiakova

Lisa Anne Racie

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Antibody to GDF8 and uses thereof

The disclosure provides novel molecules related to growth and differentiation factor 8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8 associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.

Polynucleotides encoding recombinant lubricin molecules and uses thereof

Recombinant lubricin molecules and uses thereof

Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura are provided.

This invention relates to aggrecanase polypeptides and aggrecanase polypeptide/ligand complexes, crystals of aggrecanase and aggrecanase polypeptide/ligand complexes, and related methods and software systems.

Aggrecanase structure

Truncated aggrecanase proteins and nucleotides sequences encoding them as well as processes for producing them are disclosed. Additionally, aggrecanases with amino acid mutations that lead to increased stability and expression levels in comparison with wild-type or native aggrecanases are also disclosed. Aggrecanases of the invention are especially useful for development of compositions for treatment of diseases such as osteoarthritis. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.

Truncated aggrecanase molecules

The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.

Modified ADAMTS4 molecules and method of use thereof

Novel aggrecanase proteins and the nucleotide sequences encoding them as well as processes for producing them are disclosed. Methods of identifying and developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.

Aggrecanase molecules

Growing community of inventors

Arlington, MA, United States of America

Christopher John Corcoran